Vidofludimus, also known as 4SC 101 or SC12267, is a novel orally active and potent DHODH inhibitor. In vitro, 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes. In vivo, oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. 4SC-101 may have potential for the treatment of intestinal inflammation. Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for the treatment of autoimmune diseases.
Dehydrogenase Inhibitors Related Products:
Mycophenolate mofetil; AGI-5198; SW033291; AGI-6780; Devimistat (CPI-613); Mycophenolic acid; Trilostane; Tenovin-1; Teriflunomide; Gimeracil; AG-636; AG-120 (racemic); Ivosidenib; Brequinar